Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 49

Sort by

Sort Order Select

Journal Articles

IRF4 maintenance in multiple myeloma is conserved in de novo-derived inobrodib resistance, conferring cross resistance to immunomodulatory drugs

Jason Taslim, Sophie Ball, Katrina Fordwor, Laurence Gesman, Thomas Milne, Aristeidis Chaidos, Anastasios Karadimitris, Nick Crump

Blood (2025) 146 (Supplement 1): 1521.

https://doi.org/10.1182/blood-2025-1521

Published: 2025

Journal Articles

CXXC1 is required for IRF4 chromatin binding and expression and regulates cellular fitness in lenalidomide-sensitive and -resistant myeloma cells

Pierangela Sabbattini, Nikolaos Trasanidis, Jason Taslim, Harry Whitwell, Hans Ng, Aristeidis Chaidos, Valentina Caputo, Alexia Katsarou, Maria Atta, Marco Bua, Jose Ros-Soto, Irene Roberts, Niklas Feldhahn, Nick Crump, Anastasios Karadimitris

Blood (2025) 146 (Supplement 1): 571.

https://doi.org/10.1182/blood-2025-571

Published: 2025

Journal Articles

Cancer-selective targeting of the NF-κB pathway via GADD45β/MKK7 inhibition: Results from the phase I trial of the first-in-class inhibitor, DTP3, in patients with relapsed or refractory multiple myeloma

Blood (2025) 146 (Supplement 1): 5825.

https://doi.org/10.1182/blood-2025-5825

Published: 2025

Journal Articles

Enhanced VLA4-dependent endothelial cell adhesion underpins the higher efficacy of CAR-iNKT over CAR-T cells in limiting leptomeningeal acute leukemia

Ilia Leontari, Hongwei Ren, Klesti Karaxhuku, Bryan Lye, Kanagaraju Ponnusamy, Ekaterini Himonas, Irene Roberts, Aristeidis Chaidos, Chris Halsey, Cristina Lo Celso, Anastasios Karadimitris

Blood (2025) 146 (Supplement 1): 262.

https://doi.org/10.1182/blood-2025-262

Published: 2025

Journal Articles

Randomized phase II dose optimization study of inobrodib (CCS1477), in combination with pomalidomide and dexamethasone in relapsed/refractory multiple myeloma (RRMM)

Blood (2025) 146 (Supplement 1): 4035.

https://doi.org/10.1182/blood-2025-4035

Published: 2025

Journal Articles

Evaluating inobrodib (CCS1477) in combination with teclistamab or elranatamab in patients with Relapsed/Refractory multiple myeloma; Specific cohorts within a Phase I/IIa study evaluating inobrodib in patients with advanced hematological malignancies

Dr. Emma Searle, Tomasz Knurowski, Sarah Gooding, Victoria Campbell, Sally Moore, Aristeidis Chaidos, Jennifer Travers, Thomas Creasey, Karen Clegg, Tim Somervaille, Charlotte Pawlyn

Blood (2025) 146 (Supplement 1): 8242.

https://doi.org/10.1182/blood-2025-8242

Published: 2025

Journal Articles

Revealing oncogenic enhancer regulation by epigenomic profiling of multiple myeloma and plasma cell leukemia patient samples

Katrina Fordwor, Jason Taslim, Sophie Ball, Pierangela Sabbattini, Alexia Katsarou, Thomas Milne, Anastasios Karadimitris, Aristeidis Chaidos, Nick Crump

Blood (2025) 146 (Supplement 1): 3258.

https://doi.org/10.1182/blood-2025-3258

Published: 2025

Journal Articles

An International Study of 343 Newly Diagnosed MM Patients with Acute Renal Failure Due to Cast Nephropathy: Assessment of Factors Affecting Renal Response

Blood (2024) 144 (Supplement 1): 3328.

https://doi.org/10.1182/blood-2024-200038

Published: 2024

Journal Articles

Development of Novel Invariant TCR-Anchored Bispecific Engagers to Enhance Anti-Cancer Activity of iNKT Cells

Klesti Karaxhuku, Kanagaraju Ponnusamy, Hongwei Ren, Bryan Lye, Ilia Leontari, Mehmood Zaidi, Farah Sabrin, Marco Bua, Maria Atta, Alexia Katsarou, Irene Roberts, Aristeidis Chaidos, Anastasios Karadimitris

Blood (2023) 142 (Supplement 1): 4828.

https://doi.org/10.1182/blood-2023-190598

Published: 2023

Journal Articles

Immune Graft Composition Is Important for Deepening Response and Outcome after Autologous Stem Cell Transplantation in Patients with Multiple Myeloma Who Do Not Receive Maintenance Therapy

Yeasung Lee, Francesca Bladt, Dimitrios Leonardos, Chira Mustafa, Alexia Katsarou, Maria Atta, Marco Bua, Ian Gabriel, Jose Ros-Soto, Alexandra Bazeos, Jiri Pavlu, Sandra Loaiza, Emma Bray, Farah O'Boyle, Elisabet Nadal, Richard Szydlo, Nicholas Crump, Anastasios Karadimitris, Aristeidis Chaidos

Blood (2023) 142 (Supplement 1): 759.

https://doi.org/10.1182/blood-2023-188912

Published: 2023

Journal Articles

Optimal, Off-the-Shelf, CAR-iNKT Cell Platform-Based Immunotherapy for Multiple Myeloma

Kanagaraju Ponnusamy, Lyra Randzavola, Hongwei Ren, Klesti Karaxhuku, Bryan Lye, Dimitrios Leonardos, Reza Nadafi, Irene Sarkar, Ilia Leontari, Farah Sabrin, Mehmood Zaidi, Marco Bua, Maria Atta, Alexia Katsarou, Irene Roberts, Aristeidis Chaidos, Anastasios Karadimitris

Blood (2023) 142 (Supplement 1): 3459.

https://doi.org/10.1182/blood-2023-189905

Published: 2023

Journal Articles

Systems medicine dissection of chr1q-amp reveals a novel PBX1-FOXM1 axis for targeted therapy in multiple myeloma

Nikolaos Trasanidis, Alexia Katsarou, Kanagaraju Ponnusamy, Yao-An Shen, Ioannis V. Kostopoulos, Bien Bergonia, Keren Keren, Paudel Reema, Xiaolin Xiao, Richard M. Szydlo, Pierangela M. R. Sabbattini, Irene A. G. Roberts, Holger W. Auner, Kikkeri N. Naresh, Aristeidis Chaidos, Tian-Li Wang, Luca Magnani, Valentina S. Caputo, Anastasios Karadimitris

Blood (2022) 139 (13): 1939–1953.

https://doi.org/10.1182/blood.2021014391

Published: 2022

Includes: Supplemental data

Journal Articles

Analyzing Efficacy Outcomes from the Phase 2 Study of Single-Agent Tazemetostat As Third-Line Therapy in Patients with Relapsed or Refractory Follicular Lymphoma to Identify Predictors of Response

Blood (2020) 136 (Supplement 1): 47–49.

https://doi.org/10.1182/blood-2020-137245

Published: 2020

Journal Articles

Single-Cell Transcriptional Landscapes of Human Bone Marrow Reveal Distinct Erythroid Phenotypes Underpinned By Genotype in Diamond-Blackfan Anemia

Blood (2020) 136 (Supplement 1): 1–2.

https://doi.org/10.1182/blood-2020-141535

Published: 2020

Journal Articles

Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor, in Patients with Relapsed or Refractory Follicular Lymphoma

Franck Morschhauser, MD PhD, Herve Tilly, MD PhD, Aristeidis Chaidos, Tycel J. Phillips, MD, Vincent Ribrag, MD, Philip Campbell, MBBS, FRACP, FRCPA, Damaj Gandhi Laurent, MD PhD, Wojciech Jurczak, MD PhD, Pamela McKay, MD, Stephen Opat, John Radford, Jennifer Whalen, Anand Rajarethinam, Susan Benedict Navia, Deyaa Adib, Gilles Salles, MD PhD

Blood (2019) 134 (Supplement_1): 123.

https://doi.org/10.1182/blood-2019-128096

Published: 2019

Journal Articles

Oncogenic MAF in Co-Operation with IRF4 Confers Extensive Chromatin Re-Arrangement in Plasma Cells and Generates 'Neo-Enhancers' That Regulate Genes Critical for Myeloma Biology

Alexia Katsarou, Nikolaos Trasanidis, Jaime Alvarez-Benayas, Foteini Papaleonidopoulou, Keren Keren, Ioannis V. Kostopoulos, Kanagaraju Ponnusamy, Xiaolin Xiao, Niklas Feldhahn, Irene Roberts, Evdoxia Hatjiharissi, Maria Papaioannou, Ian Sudbery, Aristeidis Chaidos, Valentina S Caputo, Anastasios Karadimitris

Blood (2019) 134 (Supplement_1): 3783.

https://doi.org/10.1182/blood-2019-122371

Published: 2019

Journal Articles

PBX1 Co-Operates with FOXM1 to Regulate Myeloma Cell Proliferation and to Define an Ultra High-Risk chr1q Gain Myeloma Patient Subgroup

Nikolaos Trasanidis, Alexia Katsarou, Bien Bergonia, Keren Keren, Ioannis V. Kostopoulos, Kanagaraju Ponnusamy, Reema Paudel, Xiaolin Xiao, Holger W Auner, MD PhD, Irene Roberts, Kikkeri Naresh, MD, Aristeidis Chaidos, Luca Magnani, Valentina S Caputo, Anastasios Karadimitris

Blood (2019) 134 (Supplement_1): 3760.

https://doi.org/10.1182/blood-2019-124109

Published: 2019

Journal Articles

Novel ZBP1-IRF3 Dependency in Multiple Myeloma Mediated By IRF3-Driven Regulation of Cell Cycle Genes

Kanagaraju Ponnusamy, Maria-Myrsini Tzioni, MS, Murshida Begum, MS, Mark E Robinson, Valentina S Caputo, Alexia Katsarou, Nikolaos Trasanidis, Xiaolin Xiao, Ioannis V. Kostopoulos, Deena Iskander, MD, Irene Roberts, Pritesh Trivedi, MSc, Holger W Auner, MD PhD, Kikkeri Naresh, MD, Aristeidis Chaidos, Anastasios Karadimitris

Blood (2019) 134 (Supplement_1): 2521.

https://doi.org/10.1182/blood-2019-125768

Published: 2019

Journal Articles

Myc and Bet Proteins Orchestrate the Early Regulatory Genome Changes Required for Osteoclast Lineage Commitment

Valentina S Caputo, Nikolaos Trasanidis, Xiaolin Xiao, Mark E Robinson, Alexia Katsarou, Kanagaraju Ponnusamy, Aristeidis Chaidos, Holger W Auner, MD PhD, Irene Roberts, Anastasios Karadimitris

Blood (2019) 134 (Supplement_1): 4329.

https://doi.org/10.1182/blood-2019-125047

Published: 2019

Journal Articles

Distinct Chromatin Accessibility Changes, Aberrant Transcription Factor Networks Combined with Novel Oncogenic Enhancers Characterise Myeloma-Initiating Genetic Events

Nikolaos Trasanidis, Jaime Alvarez-Benayas, Alexia Katsarou, Aristeidis Chaidos, Philippa C May, Kanagaraju Ponnusamy, Xiaolin Xiao, Marco Bua, MD, Maria Atta, MD, Irene Roberts, Holger W Auner, MD PhD, Evdoxia Hatjiharissi, Maria Papaioannou, Valentina S Caputo, Ian Sudbery, Anastasios Karadimitris

Blood (2019) 134 (Supplement_1): 1769.

https://doi.org/10.1182/blood-2019-124761

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

IRF4 maintenance in multiple myeloma is conserved in de novo-derived inobrodib resistance, conferring cross resistance to immunomodulatory drugs

CXXC1 is required for IRF4 chromatin binding and expression and regulates cellular fitness in lenalidomide-sensitive and -resistant myeloma cells

Cancer-selective targeting of the NF-κB pathway via GADD45β/MKK7 inhibition: Results from the phase I trial of the first-in-class inhibitor, DTP3, in patients with relapsed or refractory multiple myeloma

Enhanced VLA4-dependent endothelial cell adhesion underpins the higher efficacy of CAR-iNKT over CAR-T cells in limiting leptomeningeal acute leukemia

Randomized phase II dose optimization study of inobrodib (CCS1477), in combination with pomalidomide and dexamethasone in relapsed/refractory multiple myeloma (RRMM)

Evaluating inobrodib (CCS1477) in combination with teclistamab or elranatamab in patients with Relapsed/Refractory multiple myeloma; Specific cohorts within a Phase I/IIa study evaluating inobrodib in patients with advanced hematological malignancies

Revealing oncogenic enhancer regulation by epigenomic profiling of multiple myeloma and plasma cell leukemia patient samples

An International Study of 343 Newly Diagnosed MM Patients with Acute Renal Failure Due to Cast Nephropathy: Assessment of Factors Affecting Renal Response

Development of Novel Invariant TCR-Anchored Bispecific Engagers to Enhance Anti-Cancer Activity of iNKT Cells

Immune Graft Composition Is Important for Deepening Response and Outcome after Autologous Stem Cell Transplantation in Patients with Multiple Myeloma Who Do Not Receive Maintenance Therapy

Optimal, Off-the-Shelf, CAR-iNKT Cell Platform-Based Immunotherapy for Multiple Myeloma

Systems medicine dissection of chr1q-amp reveals a novel PBX1-FOXM1 axis for targeted therapy in multiple myeloma

Analyzing Efficacy Outcomes from the Phase 2 Study of Single-Agent Tazemetostat As Third-Line Therapy in Patients with Relapsed or Refractory Follicular Lymphoma to Identify Predictors of Response

Single-Cell Transcriptional Landscapes of Human Bone Marrow Reveal Distinct Erythroid Phenotypes Underpinned By Genotype in Diamond-Blackfan Anemia

Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor, in Patients with Relapsed or Refractory Follicular Lymphoma

Oncogenic MAF in Co-Operation with IRF4 Confers Extensive Chromatin Re-Arrangement in Plasma Cells and Generates 'Neo-Enhancers' That Regulate Genes Critical for Myeloma Biology

PBX1 Co-Operates with FOXM1 to Regulate Myeloma Cell Proliferation and to Define an Ultra High-Risk chr1q Gain Myeloma Patient Subgroup

Novel ZBP1-IRF3 Dependency in Multiple Myeloma Mediated By IRF3-Driven Regulation of Cell Cycle Genes

Myc and Bet Proteins Orchestrate the Early Regulatory Genome Changes Required for Osteoclast Lineage Commitment

Distinct Chromatin Accessibility Changes, Aberrant Transcription Factor Networks Combined with Novel Oncogenic Enhancers Characterise Myeloma-Initiating Genetic Events

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only